[Optimized antithrombotic therapy for coronary artery disease: current status and future perspectives].
Y, L. & YL, H. (2026). [Optimized antithrombotic therapy for coronary artery disease: current status and future perspectives].. Zhonghua xin xue guan bing za zhi. https://doi.org/10.3760/cma.j.cn112148-20260506-00286
Y L, YL H. [Optimized antithrombotic therapy for coronary artery disease: current status and future perspectives].. Zhonghua xin xue guan bing za zhi. 2026; doi: 10.3760/cma.j.cn112148-20260506-00286
Y L, YL H. [Optimized antithrombotic therapy for coronary artery disease: current status and future perspectives].[J]. Zhonghua xin xue guan bing za zhi. 2026. DOI: 10.3760/cma.j.cn112148-20260506-00286.
@article{y2026,
author = {Li Y and Han YL},
title = {[Optimized antithrombotic therapy for coronary artery disease: current status and future perspectives].},
journal = {Zhonghua xin xue guan bing za zhi},
year = {2026},
doi = {10.3760/cma.j.cn112148-20260506-00286},
note = {PMID: 42324100},
}
TY - JOUR AU - Li Y AU - Han YL TI - [Optimized antithrombotic therapy for coronary artery disease: current status and future perspectives]. T2 - Zhonghua xin xue guan bing za zhi PY - 2026 DO - 10.3760/cma.j.cn112148-20260506-00286 AN - PMID:42324100 ER -
抗栓治疗是冠心病综合管理的核心环节，直接决定患者缺血与出血风险的平衡及远期临床预后。近年来，随着新药研发、治疗策略迭代与风险评估技术进步，冠心病抗栓治疗正从传统标准化方案转向精准化、个体化模式。该文围绕新型抗栓药物研发进展、抗栓治疗策略革新、缺血与出血风险预测模型构建等方面，系统梳理该领域现状，剖析关键挑战，并对未来发展方向进行述评，为临床实践与科学研究提供参考。.